Literature DB >> 17938181

Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.

O Gutiérrez1, C Juan, E Cercenado, F Navarro, E Bouza, P Coll, J L Pérez, A Oliver.   

Abstract

All (236) Pseudomonas aeruginosa isolates resistant to imipenem and/or meropenem collected during a multicenter (127-hospital) study in Spain were analyzed. Carbapenem-resistant isolates were found to be more frequently resistant to all beta-lactams and non-beta-lactam antibiotics than carbapenem-susceptible isolates (P < 0.001), and up to 46% of the carbapenem-resistant isolates met the criteria used to define multidrug resistance (MDR). Pulsed-field gel electrophoresis revealed remarkable clonal diversity (165 different clones were identified), and with few exceptions, the levels of intra- and interhospital dissemination of clones were found to be low. Carbapenem resistance was driven mainly by the mutational inactivation of OprD, accompanied or not by the hyperexpression of AmpC or MexAB-OprM. Class B carbapenemases (metallo-beta-lactamases [MBLs]) were detected in a single isolate, although interestingly, this isolate belonged to one of the few epidemic clones documented. The MBL-encoding gene (bla(VIM-2)), along with the aminoglycoside resistance determinants, was transferred to strain PAO1 by electroporation, demonstrating its plasmid location. The class 1 integron harboring bla(VIM-2) was characterized as well, and two interesting features were revealed: intI1 was found to be disrupted by a 1.1-kb insertion sequence, and a previously undescribed aminoglycoside acetyltransferase-encoding gene [designated aac(6')-32] preceded bla(VIM-2). AAC(6')-32 showed 80% identity to AAC(6')-Ib' and the recently described AAC(6')-31, and when aac(6')-32 was cloned into Escherichia coli, it conferred resistance to tobramycin and reduced susceptibility to gentamicin and amikacin. Despite the currently low prevalence of epidemic clones with MDR, active surveillance is needed to detect and prevent the dissemination of these clones, particularly those producing integron- and plasmid-encoded MBLs, given their additional capacity for the intra- and interspecies spread of MDR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938181      PMCID: PMC2167976          DOI: 10.1128/AAC.00810-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  49 in total

1.  First isolation of a carbapenem-hydrolyzing beta-lactamase in Pseudomonas aeruginosa in Spain.

Authors:  Guillem Prats; Elisenda Miro; Beatriz Mirelis; Laurent Poirel; Samuel Bellais; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  A spontaneous point mutation in the aac(6')-Ib' gene results in altered substrate specificity of aminoglycoside 6'-N-acetyltransferase of a Pseudomonas fluorescens strain.

Authors:  T Lambert; M C Ploy; P Courvalin
Journal:  FEMS Microbiol Lett       Date:  1994-01-15       Impact factor: 2.742

5.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.

Authors:  David Landman; John M Quale; David Mayorga; Adedeyo Adedeji; Kalyani Vangala; Jayshree Ravishankar; Carlos Flores; Steven Brooks
Journal:  Arch Intern Med       Date:  2002-07-08

7.  Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance.

Authors:  E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.

Authors:  C Peña; A Guzmán; C Suarez; M A Dominguez; F Tubau; M Pujol; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

9.  Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  FEMS Microbiol Lett       Date:  2004-07-01       Impact factor: 2.742

10.  Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study.

Authors:  J D Cavallo; D Hocquet; P Plesiat; R Fabre; M Roussel-Delvallez
Journal:  J Antimicrob Chemother       Date:  2007-04-05       Impact factor: 5.790

View more
  57 in total

1.  Diverse mobilized class 1 integrons are common in the chromosomes of pathogenic Pseudomonas aeruginosa clinical isolates.

Authors:  Elena Martinez; Carolina Marquez; Ana Ingold; John Merlino; Steven P Djordjevic; H W Stokes; Piklu Roy Chowdhury
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

Review 2.  Antimicrobial resistance in hospitals: how concerned should we be?

Authors:  Michael R Mulvey; Andrew E Simor
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

3.  Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.

Authors:  Esther Viedma; Carlos Juan; Joshi Acosta; Laura Zamorano; Joaquín R Otero; Francisca Sanz; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

4.  Chronic respiratory infections by mucoid carbapenemase-producing Pseudomonas aeruginosa strains, a new potential public health problem.

Authors:  Carlos Juan; Olivia Gutiérrez; Feliu Renom; Margarita Garau; Carmen Gallegos; Sebastián Albertí; José Luis Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

5.  Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.

Authors:  C Juan; X Mulet; L Zamorano; S Albertí; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

6.  First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.

Authors:  Gian Maria Rossolini; Francesco Luzzaro; Roberta Migliavacca; Claudia Mugnaioli; Beatrice Pini; Filomena De Luca; Mariagrazia Perilli; Simona Pollini; Melissa Spalla; Gianfranco Amicosante; Antonio Toniolo; Laura Pagani
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

7.  Mobile genetic elements related to the diffusion of plasmid-mediated AmpC β-lactamases or carbapenemases from Enterobacteriaceae: findings from a multicenter study in Spain.

Authors:  L Zamorano; E Miró; C Juan; L Gómez; G Bou; J J González-López; L Martínez-Martínez; B Aracil; M C Conejo; A Oliver; F Navarro
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

Review 8.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

9.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.